Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma

Figure 1

Phenotype of TILs at the time of infusion. (a) Representative flow cytometry of CD3⁺, CD3⁺CD4⁺, CD3⁺CD8⁺, CD3⁺CD56⁺, CD3^-CD56⁺, CD3⁺CD8⁺PD1⁺, and CD4⁺FoxP3⁺percentage of TILs. (b) Quantitative analysis of CD3⁺, CD3⁺CD4⁺, CD3⁺CD8⁺, CD3⁺CD56⁺, CD3^-CD56⁺, CD3⁺PD1⁺, CD3⁺CD8⁺PD1⁺, CD3⁺CD8⁺PD1⁺, and CD4⁺FoxP3⁺percentage of TILs. FMO is negative control.

(a)

(b)